BIOQUAL, Inc., formerly Diagnon Corporation, develops, produces and sells diagnostic test kits incorporating monoclonal antibodies to diagnose certain anemias, infections, and parasitic diseases.
| Revenue (Most Recent Fiscal Year) | $58.59M |
| Net Income (Most Recent Fiscal Year) | $0.48M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.82 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.11 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 3.00 |
| Pre-Tax Margin (Trailing 12 Months) | -6.38% |
| Net Margin (Trailing 12 Months) | -4.34% |
| Return on Equity (Trailing 12 Months) | -5.82% |
| Return on Assets (Trailing 12 Months) | -3.79% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.08 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.08 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.39 |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 0.89M |
| Free Float | 0.54M |
| Market Capitalization | $40.25M |
| Average Volume (Last 20 Days) | 257.50 |
| Beta (Past 60 Months) | -0.09 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 39.24% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.50 |
| Dividend Yield (Based on Last Quarter) | 1.11% |